ProPhase Labs Announces Financial Results for the Year Ended December 31, 2023 and Significant Progress in Its Strategic Initiatives
Garden City, NY, March 15, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase” or the “Company”), a next-generation biopharma, genomics, and diagnostics company, today reported its financial and operational results for the full-year ended December 31, 2023.
- With this significant repositioning completed, Nebula Genomics can now deliver low-cost, high-precision genomic diagnostics across North America and the global market.
- This agreement presents the possibility for significant expansion of its global footprint and paves the way for prospective future revenue streams.
- Research and development costs for the year ended December 31, 2023 and 2022 were $1.4 million and $0.7 million, respectively.
- Diluted earnings per share for the years ended December 31, 2023 and 2022 were $(0.98) and $1.02, respectively.